Abstract
The pathogenesis of ulcerative colitis involves activated granulocytes, monocytes and macrophages. Apheresis has been suggested as a safe and effective treatment for ulcerative colitis. This Practice Point commentary discusses the findings and limitations of a multicenter, randomized, sham-controlled trial by Sands and colleagues, who investigated the efficacy of leukocyte apheresis in patients with moderate-to-severe ulcerative colitis. The results of this trial show no significant difference in outcomes between sham-treated and apheresis-treated patients. Rates of clinical remission, clinical response, endoscopic remission and response, and changes in Mayo score and Quality of Life score were similar between sham-treated and apheresis-treated patients. These findings contradict the results of previous studies, and serve to emphasize the importance of performing rigorous and appropriately designed clinical trials with established end points to determine the efficacy of therapy in IBD. The same standard of rigorous evaluation must be applied to new devices as is applied to pharmaceutical products.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ljung T et al. (2007) Granulocyte,monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scan J Gastroenterol 42: 221–227
Sands BE et al. (2008) A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 135: 400–409
Naganuma M et al. (2004) Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 10: 251–257
Yamamoto T et al. (2004) Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 20: 783–792
5 Maiden L et al. (2008) Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 14: 1413–1418
Sakuraba A et al. (2008) A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol 43: 51–56
Sawada K et al. (2005) Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 100: 1362–1369
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ghosh, S., Kaplan, G. & Panaccione, R. Granulocyte–monocyte apheresis for the treatment of ulcerative colitis—is this the end of the road?. Nat Rev Gastroenterol Hepatol 6, 6–7 (2009). https://doi.org/10.1038/ncpgasthep1299
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep1299
This article is cited by
-
Preliminary studies for the development of a second generation granulocytapheresis (G-CAP) column
Journal of Artificial Organs (2010)